Serum immune complex containing thrombospondin-1: a novel biomarker for early rheumatoid arthritis

Ohyama, Kaname; Kawakami, Atsushi; Tamai, Mami; Baba, Miyako; Kishikawa, Naoya; Kuroda, Naotaka

Annals of the Rheumatic Diseases, 71(11), pp.1916-1917; 2012

© 2012 BMJ Publishing Group Ltd & European League Against Rheumatism. All rights reserved.

http://hdl.handle.net/10069/30708

NAOSITE: Nagasaki University’s Academic Output SITE
Serum immune complex containing thrombospondin-1: a novel biomarker for early rheumatoid arthritis

The diagnosis of rheumatoid arthritis (RA) is based on classification criteria set by the 2010 RA classification criteria including serological assessment of rheumatoid factor (RF) and anticitrulline-containing protein/peptide (anti-CCP) antibody.\textsuperscript{1, 2} Anti-CCP antibody is specific (94–99%) for RA; however, 25% of patients with established RA and 40% of patients with early RA are negative for this marker.\textsuperscript{3, 4} Novel biomarkers, especially for early RA and/or for RA lacking RF and anti-CCP antibody markers (ie, seronegative RA) are therefore urgently required. Circulating immune complexes (CICs) present in the human
body are likely to contain many different antigens that may reflect underlying disease, so antigens incorporated into CICs are promising candidates for diagnostic biomarkers. We developed a novel proteomic strategy (immune complexome analysis) to identify and profile antigens in CICs and used this method to analyse CICs in patients with established RA and controls (healthy donors and patients with osteoarthritis). CIC-associated thrombospondin-1 (TSP-1) was found in 81% and CIC-associated platelet factor 4 (PF4) in 52% of patients with established RA, but neither protein was found in CICs from any of the controls. Both proteins are known as endogenous inhibitors of angiogenesis, and the formation of CICs may promote angiogenesis. We evaluated the diagnostic potential of CIC-associated TSP-1 and CIC-associated PF4 in patients with early RA divided into seropositive and seronegative groups.

Serum samples were collected from 25 disease-modifying antirheumatic drug (DMARD)-naive seropositive patients with early RA (mean±SD age 52.8±18.4 years; 21 women; disease duration 0.25–12 months; CRP 0.01–8.55 mg/dl) and 15 seronegative patients with early RA (mean±SD age 60.5±17.9 years; 8 women; disease duration 1–6 months; CRP 0.02–14.4 mg/dl) at Nagasaki University Hospital. All the seropositive patients were positive for RF and 20 were positive for anti-CCP antibody, while all the seronegative patients were negative for both RF and anti-CCP antibody. The diagnosis of RA was made by the 2010 RA classification criteria as well as administration of DMARDs within the first 12 months. Serum samples from 16 patients with Sjögren’s syndrome (SS) (mean±SD age 60.9±13.0 years) and 14 patients with systemic lupus erythematosus (SLE) (mean±SD age 42.6±12.4 years) who fulfilled the international criteria for the diagnosis of SS and SLE and 11 healthy donors (mean±SD age 49.5±10.3 years) were used as controls. CICs purified by magnetic beads with immobilised protein G were reduced and alkylated, followed by tryptic digestion. The peptide mixture (1 µl) was subjected to nano-liquid chromatography/electrospray ionization/tandem mass spectrometry. More details of the analytical method can be found in our earlier report.

As shown in table 1, CIC-associated TSP-1 was found only in patients with early RA and was not found in disease controls (patients with SS or SLE) or healthy donors (100% specific). Twenty-two (55%) of the total of 40 patients with early RA (56% (14/25) of the seropositive patients and 53% (8/15) of the seronegative patients) had CIC-associated TSP-1. PF4-containing CICs were found in only three patients (8%) with early RA compared with 52% of the patients with established RA. These PF4-containing CICs may therefore promote disease progression.

In conclusion, we have shown that CIC-associated TSP-1 has high potential as a novel biomarker for diagnosing early and/or seronegative RA. Further analyses using a large number of patients are warranted to determine the clinical benefit of using this novel biomarker.

**Kaname Ohyama,1,2 Atsushi Kawakami,3 Mami Tamai,3 Miyako Baba,1 Naoya Kishikawa,1 Naotaka Kuroda1**

1 Department of Environmental and Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
2 Nagasaki University Research Centre for Genomic Instability and Carcinogenesis (NRCIC), Nagasaki, Japan
3 Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

**Correspondence to** Naotaka Kuroda, Department of Environmental and Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan; n-kuro@nagasaki-u.ac.jp

**Funding** This work was supported by Special Coordination Funds for Promoting Science and Technology from Japan Science and Technology Agency, a Grant-in-Aid for Young Scientist (B; grant no. 22790160), Challenging Exploratory Research (grant no. 23658301) and Scientific Research (C; grant no. 23591438) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

**Competing interests** None.

**Ethics approval** This study was conducted with the approval of the Institutional Review Board of Nagasaki University.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Received** 4 January 2012
**Accepted** 19 April 2012
**Published Online First** 7 June 2012


**REFERENCES**

Serum immune complex containing thrombospondin-1: a novel biomarker for early rheumatoid arthritis

Kaname Ohyama, Atsushi Kawakami, Mami Tamai, et al.

Ann Rheum Dis 2012 71: 1916-1917 originally published online June 7, 2012
doi: 10.1136/annrheumdis-2012-201305

Updated information and services can be found at:
http://ard.bmj.com/content/71/11/1916.full.html

These include:

References
This article cites 10 articles, 4 of which can be accessed free at:
http://ard.bmj.com/content/71/11/1916.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/